June 4, 2025

If you or a loved one has Type 1 diabetes (T1D), let your voice be heard!

The U.S. Food and Drug Administration (FDA) is considering the approval of sotagliflozin as a new treatment for glycemic control for the 1.7 million U.S. adults with Type 1 diabetes (T1D). Sotagliflozin is already approved in Europe and is urgently needed in the United States.

Every day without this potentially life-changing treatment is a day that people with T1D must continue to endure an exhausting regimen with limited options and with poor outcomes. Learn more by clicking here.

Call upon the FDA and FDA commissioner Makary to prioritize the approval of sotagliflozin, a treatment that was approved in Europe based on the same data five years ago. Join others who are eager for innovative and effective options for T1D.

Please join the efforts to bring this life-improving medication to those who need it the most. Every voice matters. Let your voice be heard. Ask FDA to give our community the chance to improve our daily lives and reduce serious complications. Click Here to Act Now.
#MAHA

Thank you for supporting the T1D community.

STEVE EDELMAN, MD
Founder and Director
Taking Control Of Your Diabetes